Skip to content

Beth Marsh

5 papers in the library · 399 citations · publishing 2019-2022

Papers

Sort Most recent Most cited

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review - CORRIGENDUM.

BJPsych Open January 18, 2022 Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al. 28 citations

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

American Journal of Psychiatry January 11, 2022 Meryem Grabski, Amy Mcandrew, Will Lawn et al. 169 citations

OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol...

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review

BJPsych Open December 23, 2021 Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al. 180 citations

Background In the past two decades, subanaesthetic doses of ketamine have been demonstrated to have rapid and sustained antidepressant effects, and accumulating research has demonstrated ketamine's therapeutic effects for a range of psychiatric conditions. Aims In light of these findings surrounding ketamine's psychotherapeutic potential, we systematically review the extant evidence on...

Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.

Behavioural Brain Research August 17, 2020 Meryem Grabski, Anna Borissova, Beth Marsh et al.

Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions. While the underlying mechanisms remain unclear, it has been hypothesised that ketamine's acute psychoactive effects may be associated with...

Greater empathy in MDMA users

Journal of Psychopharmacology February 5, 2019 Molly Carlyle, Tobias Stevens, Leah Fawaz et al. 22 citations

Background: 3,4-Methylenedioxymethamphetamine (MDMA) is widely known for its positive acute effects on social behaviour, such as increasing empathy, whilst also attenuating the negative impact of social exclusion. However there is a scarcity of research that investigates the long-term impact of recreational MDMA use on these fundamental social processes. Method: Sixty-seven individuals were...